Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-2189 in advanced solid tumors
NCT05851092Phase 1Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hrs-2189 in advanced malignant solid tumor, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Adverse Events and Serious Adverse Events, Dose Limiting Toxicity up to 35 days and 2 more. Started May 2023; status: recruiting.
02
Drugs
hrs-2189
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05851092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851092.